Active	Status	Sponsor type	Region	Phase	Filter
4 Active 3 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
O'Regan, Ruth
NCT04886531: Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers	Recruiting	2	48	US	Neratinib, Nerlynx, Letrozole (L) or Anastrozole (A), Femara, Arimidex, Trastuzumab, Herceptin	Ruth O'Regan, Puma Biotechnology, Inc., University of Rochester	Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer	09/25	10/25
NCT03090165: Ribociclib and Bicalutamide in AR+ TNBC	Recruiting	1/2	37	US	ribociclib, LEE011, Bicalutamide	Kari Wisinski, Novartis, Big Ten Cancer Research Consortium, University of Wisconsin, Madison	Triple Negative Breast Cancer	09/25	09/25